Consensus C4 Therapeutics, Inc.

Stocks

CCCC

US12529R1077

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-10-19 EDT			5-day change	1st Jan Change
2.890 ^USD	+4.52%		-5.56%	+51.31%

09-25	C4 Therapeutics, Inc. Presents New Biomarker Data from Cemsidomide Phase 1 Trial With Dexamethasone and Phase 1b Trial With Elranatamab in Relapsed/Refractory Multiple Myeloma	CI
08-11	C4 Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Evolution of the Average Target: C4 Therapeutics, Inc.

Evolution of the Target Price: C4 Therapeutics, Inc.

Changes in Analyst Recommendations: C4 Therapeutics, Inc.

4ed80dc529fd55108f1690b53f277.3J2WBtvAvSZLOrE3RB5iA1XDaL08kr7pkQIGtNGVYJs.iPb5M6O2znYvVP5tCmYAazqiOvp40PDd4kZr_7qnBdS069A14q3sSAlU9A~497348055cf4073fa026828499d1e196

Analysts' recommendations: C4 Therapeutics, Inc.

12-02	TD Cowen Initiates C4 Therapeutics at Buy	MT
25-09-17	Barclays Initiates C4 Therapeutics at Overweight With $8 Price Target	MT
25-09-15	Stephens Upgrades C4 Therapeutics to Overweight From Equalweight, Adjusts Price Target to $6 From $3	MT
25-03-03	UBS Adjusts C4 Therapeutics Price Target to $3.50 From $4, Maintains Neutral Rating	MT
25-02-14	UBS Downgrades C4 Therapeutics to Neutral From Buy, Adjusts Price Target to $4 From $18	MT
24-12-19	Wells Fargo Upgrades C4 Therapeutics to Overweight From Equalweight, Raises Price Target to $12 From $8	MT
24-09-16	Evercore ISI Lifts Price Target on C4 Therapeutics to $10 From $9, Keeps Outperform Rating	MT
24-05-09	Stifel Adjusts Price Target on C4 Therapeutics to $14 From $13, Maintains Buy Rating	MT
24-02-26	Morgan Stanley Adjusts Price Target on C4 Therapeutics to $8 From $1, Maintains Equal-Weight Rating	MT
24-01-29	JPMorgan Upgrades C4 Therapeutics to Neutral From Underweight, Price Target is $6	MT
23-12-13	Stifel Upgrades C4 Therapeutics to Buy From Hold, Raises Price Target to $12 From $2	MT
23-11-06	Morgan Stanley Upgrades C4 Therapeutics to Equalweight From Underweight, Cuts Price Target to $1 From $3	MT
23-11-03	BMO Capital Adjusts Price Target on C4 Therapeutics to $16 From $18, Keeps Outperform Rating	MT
23-11-02	HC Wainwright Adjusts Price Target on C4 Therapeutics to $7 From $17, Keeps Buy Rating	MT
23-08-09	HC Wainwright Adjusts Price Target on C4 Therapeutics to $17 From $25, Maintains Buy Rating	MT
23-07-21	UBS Adjusts C4 Therapeutics Price Target to $20 From $22, Maintains Buy Rating	MT
23-05-30	Evercore ISI Adjusts C4 Therapeutics Price Target to $10 From $20, Maintains Outperform Rating	MT
23-05-12	Morgan Stanley Adjusts Price Target on C4 Therapeutics to $3 From $5, Maintains Underweight Rating	MT
23-05-08	HC Wainwright Adjusts C4 Therapeutics' Price Target to $25 From $35, Keeps Buy Rating	MT
23-03-28	BofA Securities Lowers Price Target on C4 Therapeutics to $5 From $11, Maintains Neutral Rating	MT
23-02-27	Morgan Stanley Adjusts Price Target on C4 Therapeutics to $5 From $6, Maintains Underweight Rating	MT
23-02-24	UBS Adjusts C4 Therapeutics Price Target to $22 From $24, Maintains Buy Rating	MT
23-02-24	JPMorgan Chase Downgrades C4 Therapeutics to Underweight From Neutral, Lowers Price Target to $5 From $15	MT
22-11-08	Wells Fargo Adjusts Price Target on C4 Therapeutics to $11 From $12, Maintains Equal-Weight Rating	MT
22-11-04	UBS Adjusts C4 Therapeutics Price Target to $24 From $26, Maintains Buy Rating	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	C4 THERAPEUTICS, INC.					+344.88%
	WUXI APPTEC CO., LTD.					+30.97%
	LONZA GROUP AG					+13.23%
	ARGENX SE					+38.42%
	IQVIA HOLDINGS INC.					+13.19%
	BEONE MEDICINES AG					+17.91%
	REVOLUTION MEDICINES, INC.					+41.56%
	CELLTRION, INC.					+35.14%
	WUXI BIOLOGICS (CAYMAN) INC.					+24.78%
	GENMAB A/S					+9.2%
	Average					+56.93%
	Weighted average by Cap.					+26.05%